Treatment with somatostatin analogues may delay progression of neuroendocrine tumours

Affiliations

Editorial

Eva Tiensuu Janson. Acta Oncol. 2014 Oct.

. 2014 Oct;53(10):1283.

doi: 10.3109/0284186X.2014.966921.

¹ Department of Medical Sciences, Endocrine Oncology, Uppsala University , Uppsala , Sweden.

No abstract available

Comment on

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. Rinke A, et al. J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510. Epub 2009 Aug 24. J Clin Oncol. 2009. PMID: 19704057 Clinical Trial.